| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP4712-5mg | 5mg | $450.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Ajuforrestin B (CAS No.: 708277-48-9) is an active compound derived from natural plants that has attracted widespread attention in recent years due to its remarkable antibacterial activity. With the increasing severity of antimicrobial resistance, developing new antimicrobials has become an urgent need in the global public health sector. Natural products, as important resources for drug discovery, have become a key direction in antimicrobial drug development due to their structural diversity and rich biological activity. As a natural product with potential antibacterial effects, arteacetic in dysentery has a unique chemical structure and multi-target mechanism of action, providing new ideas for the development of novel antimicrobial drugs.
This review aims to systematically summarize the chemical structure and physicochemical properties of dysentery artemisiacin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, explore its clinical application prospects and future research directions, and provide reference for researchers in related fields.
The molecular weight of artemiacetic in dysentery is 326.3920, with a molecular formula of C_20H_26O_4 (specific molecular formula should be confirmed according to literature). Its LogP value is 4.5460, indicating that the compound has high lipid solubility and facilitates penetration of cell membranes, but its water solubility is relatively low (0.0194 mg/mL), indicating limited solubility in the aqueous phase. The topological pole surface area (TPSA) is 66.76 Ų, classifying it as a moderately polar compound that may affect its absorption and distribution characteristics.
Structurally, artephenyl belongs to the terpene class or natural products of terpenoids, featuring multiple cyclic structures and functional groups, which give it specific biological activity. Its low blood-brain barrier permeability indicates that the compound has difficulty entering the central nervous system, potentially reducing the risk of CNS-related toxicity. The hERG channel inhibition test results were negative, suggesting that arteacetic acid has a relatively high potential safety for cardiac electrophysiology. The Ames mutagenic test result was 0.0, indicating no significant genotoxicity and meeting safety requirements.
Artesy Acetosetin is mainly isolated from plants of the genus Ajuga (Ajuga spp.). Artemisia plants are widely distributed in parts of Asia and Europe, and have traditionally been used to treat digestive system diseases and infectious diseases. The extraction of this compound typically uses organic solvent extraction combined with chromatography separation technology.
Common extraction processes include:
1. Raw material preparation: Collect the dried above-ground parts or roots of the Zhizhihao plant and crush it into fine powder.
2. Solvent extraction: Extraction is carried out using organic solvents such as ethanol, methanol, or ethyl acetate, and extraction takes several hours to several tens of hours at room temperature or under reflux conditions.
3. Concentration and separation: After vacuum concentration, the extract is separated and purified using silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and other techniques.
4. Structural identification: Confirm the compound structure using methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR).
In recent years, ultrasound-assisted extraction and microwave-assisted extraction technologies have also been applied to improve the extraction efficiency and purity of artemisinacetic extraction.
The main pharmacological activity of arteacetic in stopping dysentery is concentrated in its antibacterial effect. In vitro experiments have shown that this compound inhibits various bacteria, including Gram-positive and Gram-negative bacteria. Its antibacterial spectrum covers common pathogens such as Staphylococcus aureus, Escherichia coli, and Streptococcus pneumoniae.
In antibacterial activity evaluation, artemiacetin showed a relatively low minimum inhibitory concentration (MIC), demonstrating strong antibacterial activity. In addition, artemiacetic acid also exhibits certain inhibitory effects on fungi such as Candida albicans, suggesting its potential broad-spectrum antimicrobial activity.
Besides antibacterial effects, some studies have also reported that arteacetic for dysentery has anti-inflammatory and antioxidant auxiliary pharmacological effects, which may synergistically enhance its anti-infective effects.
The antibacterial mechanism of arteacetic in stopping dysentery involves multiple key targets, demonstrating the characteristic of multi-target coordinated inhibition. Known related targets include:
Dysentery Etigoethyl Acts on the above multiple targets, interfering with bacterial DNA replication, cell division, metabolism, synthesis, and drug resistance mechanisms, demonstrating strong antibacterial activity and a low risk of resistance.
The drug-making evaluation of arteacetic for dysentery showed good safety and pharmacodynamic characteristics. Its higher LogP value indicates good lipid solubility, which facilitates cell membrane penetration, but its low water solubility may limit its oral absorption and bioavailability. TPSA is moderate, suggesting it may have good membrane permeability.
The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. The hERG channel's inhibition-negative and non-mutagenic results further support its safety.
Pharmacokinetics, although there is currently limited data on in vivo metabolism and excretion of artegoethylene for dysentery, its structural characteristics suggest it may be metabolized by the liver, mainly excreted by the kidneys or bile. In the future, in vivo pharmacokinetic studies are needed to clarify its absorption, distribution, metabolism, and excretion (ADME) characteristics to guide dosage formulation design and administration regimens.
As a multi-target natural antibacterial product, arteacetic in dysentery demonstrates broad-spectrum antibacterial activity and good safety, showing potential as a candidate molecule for novel antimicrobial drugs. Its multi-target mechanism helps overcome the resistance issues of traditional antimicrobial drugs, especially in combating resistant strains.
Future research should focus on the following aspects:
1. In-depth pharmacokinetics and toxicology studies to clarify its in vivo behavior and long-term safety.
2. Structural optimization and derivative development, improving water solubility and bioavailability through chemical modification, thereby enhancing efficacy.
3. Combination drug studies to explore synergistic effects with existing antimicrobials to enhance clinical efficacy.
4. Preclinical animal model validation to evaluate its in vivo anti-infective efficacy and safety, laying the foundation for clinical trials.
5. Deepen mechanism research by using molecular biology and structural biology methods to further clarify its target binding patterns and pathways.
With the intensification of antimicrobial resistance issues, the development and application prospects for dysentery and artemiacetin are broad, and are expected to provide new breakthroughs for antimicrobial drug research.
As a natural product derived from the genus Artemisia, Erygium Acetin shows great potential in antimicrobial drug development due to its unique chemical structure and multi-target antibacterial mechanism. Its excellent safety profile and multi-target action offer new strategies to overcome bacterial resistance. Although its clinical application is still in its early stages, with deeper research on pharmacokinetics, toxicology, and mechanisms, artemisinin for dysentery is expected to become an important candidate for future antibacterial therapy.
Future research should focus on enhancing drug characteristics, clarifying clinical indications, and optimizing dosing regimens to promote its transition from laboratory to clinical application, contributing to global antimicrobial drug innovation.
